Fig. 5

The prognostic signature as a predictive biomarker for immunotherapy in BRCA. (a) Scatter plots depicting the negative correlation between risk score of the prognostic signature and the expression of PD-L1, PD-1 and CTLA-4. The spearman correlation is used in calculations. TIDE scores in high-risk and low-risk score groups in (b) TCGA-BRCA cohort and (c) validation cohorts including METABRIC, GSE21653 and GSE58812. Significance P values were calculated using Wilcoxon rank sum test.